NAD+ Without Prescription: Nobody Else Checks the Batch

Searches for NAD+ without prescription assume a single rule being worked around. There is no single rule, because the phrase covers three different transactions: a clinic administering an infusion, a pharmacy compounding a preparation against a prescription, and a research supplier selling bulk material under research-use terms.

Only one of those three turns on the federal document that most pages on this topic reference and many of them misquote. This page reproduces what that document says, names the entry it is easy to confuse it with, and is careful about the difference between enforcement discretion and approval, because that difference is the whole answer.

Underneath all three sits a plainer fact that gets less attention than the categories do. No regulator has assessed the batch in front of you in any of the three, so whoever reads the certificate is the only party who checks it. In two of them that person is a pharmacist. In the third it is you.

The research-use listing this page keeps returning to:

NAD+ without prescription describes three transactions

Set them side by side and most of the confusion resolves, because the paperwork behind each one is different and so is the party carrying the obligation.

Read down the third column rather than the first. The first two transactions have an accountable professional in them and a rule set that can be failed. The third has a document, and the quality of that document is the entire protection available to the person paying. That is why this site treats the certificate as the object of interest rather than the storefront.

What category 1 says, in FDA's words

Section 503A of the Federal Food, Drug, and Cosmetic Act governs compounding by state-licensed pharmacies and physicians. While it evaluates substances nominated for the 503A bulks list, FDA operates an interim policy that sorts nominated substances into three categories, and it describes the first one as follows:

Category 1 substances may be eligible for inclusion on the 503A bulks list, were nominated with sufficient supporting information for FDA to evaluate them, and do not appear on any other list. FDA does not intend to take action against a compounder for compounding drugs using bulk drug substances listed in category 1, provided that the conditions described in the guidance document are met.

Every load-bearing word in that passage is a limit. Does not intend to take action is enforcement discretion, not permission, and it is directed at compounders rather than at buyers. May be eligible is a pending question. Provided that the conditions are met attaches obligations that sit elsewhere. And the heading of the category itself is bulk drug substances under evaluation.

FDA also states that substances in category 1 may continue within the interim policy only until the agency decides on their inclusion on the 503A bulks list, or unless it removes them based on, for example, information about safety risks. Separately, it has said it does not intend to place substances nominated on or after January 7, 2025 into these categories at all. This is a snapshot of an unfinished process, and it should be read as one.

Here is where the relevant entries actually sit, from the FDA category document updated May 14, 2026.

The source is the FDA page describing the interim policy and the category list it links to. Both are worth opening rather than taking on trust from us, which is also the point of the next section.

The entry that is easy to quote wrongly

Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate is a longer, more formal name, and it sits in category 3 rather than category 1. That is a genuinely different position: FDA describes category 3 substances as nominated with insufficient supporting information for it to evaluate them, states they are not eligible for the policy that applies to category 1, and says the agency would consider taking action against a compounder using them under its general enforcement policies.

The trap is obvious once seen. Anyone who searches the category document for nicotinamide adenine dinucleotide will get hits in two different sections, and a writer in a hurry can read a category 3 heading above a name that looks like the substance they were researching. That is the most plausible origin of the claim, which turns up repeatedly, that NAD+ is restricted or banned from compounding. The plain NAD entry has never been in category 2 and is not in category 3.

The habit that protects you is small and it applies well beyond this compound: read the exact substance name on the list, including salt and hydrate forms, rather than the name you were looking for. Naming conventions are the mechanism by which a regulatory claim goes wrong.

What the category does not do for a private buyer

It is tempting to read a category 1 listing as official reassurance. It is not, for three separate reasons.

• It addresses compounders, not purchasers. The policy describes what FDA does or does not intend to do about pharmacies and physicians compounding with a substance. It is not a statement about a private purchase and confers nothing on one.
• It is about the substance, not about a batch. No listing says anything about the material in any particular container. A category 1 substance can arrive as a food-grade powder from a repackager, which is precisely the scenario FDA wrote a separate notice about.
• The conditions carry the weight. The permission is conditional on the guidance conditions being met, and among those conditions is the requirement that bulk drug substances be accompanied by a valid certificate of analysis and have been manufactured by an establishment registered under section 510. The compounding route, read honestly, is a documentary route.

That third bullet is why a page about prescriptions ends up back at certificates. The federal framework does not ask whether the material was expensive or domestic. It asks whether provenance and analysis exist in a form someone can produce on request.

The question a prescription would not have answered anyway

Assume the prescription route is available and taken. There is still a purchase decision upstream that the prescription does not settle, and FDA has already described it going wrong.

In a notice whose content is current as of October 2024, the agency stated that it is aware of compounders using food-grade nicotinamide adenine dinucleotide sold by repackagers to make intravenous products, that food-grade ingredients are not suitable for compounding sterile drugs without appropriate processing because of the high risk of contamination with microbes and endotoxins, and that it had received adverse event reports following use of NAD+ injectable drugs, including severe chills, shaking, vomiting and fatigue, some requiring medical treatment, consistent with excessive levels of endotoxins.

Those preparations were compounded. A prescription existed. The failure was in the starting material, and the assay that would have caught it is a bacterial endotoxins test on the bulk substance, not anything on a prescription pad. Whichever of the three transactions you are in, that is the question to carry: pharmaceutical grade or food grade, and is there an LAL result for this lot. The technical version of the argument is on our injectable formats page, and the supplier-selection version is in our sourcing criteria.

FDA also publishes a general questions and answers page on compounding that is worth reading once if you are considering the pharmacy route, since it sets out plainly that compounded drugs are not FDA-approved products.

What no route establishes

None of the three transactions above is evidence that infusing NAD+ does anything. The coenzyme itself is thoroughly characterised: it carries electrons through central energy metabolism and is consumed as a substrate by sirtuins, PARPs and related enzymes, a literature reviewed by Covarrubias and colleagues. That work is overwhelmingly cellular and preclinical.

The marketing that surrounds NAD+ infusions runs a long way ahead of that. Clinics advertise it for conditions this site will not repeat as claims, and the absence of an approved product is not an oversight to be routed around; it is the accurate reflection of an unfinished evidence base. Precursor compounds such as nicotinamide mononucleotide and nicotinamide riboside are sold through a different channel again, with their own separate regulatory history that this page does not attempt to state.

Dosing is out of scope here and deliberately so: this page is about which transaction you are in and what document sits behind it. Nothing on it describes or implies human use.